Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Neoadjuvant letrozol plus taselisib bij ER+ HER2- stadium I-III borstkanker
okt 2019 | Borstkanker